• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    P3 Health Partners Announces First Quarter 2025 Results

    5/15/25 4:18:00 PM ET
    $PIII
    Medical/Nursing Services
    Health Care
    Get the next $PIII alert in real time by email

     Affirming 2025 guidance

    Management to Host Conference Call and Webcast May 15, 2025 at 4:30 PM ET

    P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2025, and affirmed its 2025 guidance.

    "Our physician-led care enablement model continues to differentiate P3, delivering meaningful improvements in quality measures and cost management through deeper provider partnerships," said Aric Coffman, CEO of P3. "Our turnaround plan is ahead of schedule, with three of four markets already achieving breakeven or better in Q1. Beyond our original plan, we've identified additional value creation opportunities through our enhanced complex care programs and payment integrity initiatives. We remain committed to our long-term strategic vision, making targeted investments in technology infrastructure and innovative clinical programs to drive sustainable value for our stakeholders."

    First Quarter 2025 Financial Results

    • Average at-risk membership was 115,900 members for the first quarter, a decrease of 8% compared to the full year average membership from the prior year. The decrease reflects previously disclosed network and payer rationalization.
    • Per-member funding PMPM was $1,063, an increase of 8% compared to the per-member funding PMPM from full year 2024.
    • Total revenue was $373.2 million, a decrease of 4% compared to $388.5 million in the first quarter of the prior year.
    • Medical margin(1) was $17.2 million compared to $36.6 million in the first quarter of the prior year. Medical Margin included a negative $23 million net impact from prior year claims related to a single payer. Medical margin PMPM(1) was $49 compared to a medical margin PMPM of $96 in the first quarter of the prior year.
    • Adjusted EBITDA loss(1) was $22.2 million compared to an Adjusted EBITDA loss(1) of $19.8 million in the first quarter of the prior year. Adjusted EBITDA loss included a negative $9 million net impact from prior year claims and retroactive adjustments related to a single payer. Adjusted EBITDA loss PMPM(1) was $64 compared to Adjusted EBITDA loss PMPM of $52 in the first quarter of the prior year.

    Fiscal 2025 Guidance

     

    Year Ended December 31, 2025

     

    Low

    High

    At-risk Members(2)

    109,000

    119,000

    Total Revenues (in millions)

    $

    1,350

    $

    1,500

    Medical Margin(1)(3) (in millions)

    $

    174

    $

    210

    Medical Margin(3) PMPM

    $

    133

    $

    147

    Adjusted EBITDA(3) (in millions)

    $

    (35)

    $

    5

    (1)

     

    Adjusted EBITDA, Adjusted EBITDA per member, per month ("PMPM"), medical margin, and medical margin PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures, if applicable, and more information regarding the Company's use of non-GAAP financial measures, please see the section titled "Non-GAAP Financial Measures."

    (2)

     

    See "Key Performance Metrics" for additional information on how the Company defines "at-risk members."

    (3)

     

    The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA, medical margin and medical margin PMPM to net income (loss), gross profit and gross profit PMPM, the most directly comparable GAAP measures, respectively, and has not provided forward-looking guidance for net income (loss), because of the uncertainty around certain items that may impact net income (loss), gross profit (loss) or gross profit (loss) PMPM that are not within our control or cannot be reasonably predicted without unreasonable effort. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Non-GAAP Financial Measures" below.

    The foregoing 2025 outlook statement represents management's current estimate as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the "Cautionary Note Regarding Forward-Looking Statements" included in this release. Management does not assume any obligation to update these estimates.

    Management to Host Conference Call and Webcast on May 15, 2025 at 4:30 PM ET

    Title & Webcast

    P3 Health First Quarter Earnings Conference Call

    Date & Time

    May 15, 2025, 4:30pm Eastern Time

    Conference Call Details

    Toll-Free 1-833-316-0546 (US)

    International 1-412-317-0692

     

    Ask to be joined into the P3 Health Partners call

    The conference call will also be webcast live in the "Events & Presentations" section of the Investor page of the P3 website (ir.p3hp.org). The Company's press release will be available at ir.p3hp.org website in advance of the conference call. An archived recording of the webcast will be available at ir.p3hp.org for a period of 90 days following the conference call.

    About P3 Health Partners (NASDAQ:PIII):

    P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,800 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 27 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient's care within the healthcare system. For more information, visit https://p3hp.org/ and follow us on LinkedIn and Facebook.com/p3healthpartners.

    Non-GAAP Financial Measures

    In addition to the financial results prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP"), this press release contains certain non-GAAP financial measures as defined by the SEC rules, including Adjusted EBITDA and Adjusted EBITDA PMPM, medical margin, medical margin PMPM, and adjusted operating expense. EBITDA is defined as GAAP net income (loss) before (i) interest, (ii) income taxes and (iii) depreciation and amortization. Adjusted EBITDA is defined as EBITDA, further adjusted to exclude the effect of certain supplemental adjustments, such as (i) mark-to-market warrant gain/loss, (ii) premium deficiency reserves, (iii) equity-based compensation expense, (iv) certain transaction and other related costs and (v) certain other items that we believe are not indicative of our core operating performances. Adjusted EBITDA PMPM is defined as Adjusted EBITDA divided by the number of at-risk Medicare members each month divided by the number of months in the period. We believe these non‐GAAP financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other similar companies. Medical margin represents the amount earned from capitation revenue after medical claims expenses are deducted and medical margin PMPM is defined as medical margin divided by the number of at-risk Medicare members each month divided by the number of months in the period. Medical claims expenses represent costs incurred for medical services provided to our members. As our platform grows and matures over time, we expect medical margin to increase in absolute dollars; however, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. Adjusted operating expense is defined as total operating expense excluding depreciation and amortization and costs that management believes are non-core to the underlying operations of the Company, consisting of (i) medical expense, (ii) premium deficiency reserves, (iii) equity-based compensation, and (iv) certain other items that we believe are not indicative or our core operating performance. We do not consider these non‐GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non‐GAAP financial measures. In addition, other companies may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. The tables at the end of this press release present a reconciliation of Adjusted EBITDA to net income (loss), medical margin to gross profit, and adjusted operating expense to operating expense, which are the most directly comparable financial measures calculated in accordance with GAAP.

    Key Performance Metrics

    In addition to our GAAP and non-GAAP financial information, the Company also monitors "at-risk members" to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. At-risk membership represents the approximate number of Medicare members for whom we receive a fixed percentage of premium under capitation arrangements as of the end of a particular period.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements address various matters, including the Company's future expected growth strategy and operating performance; and the Company's ability to execute on its identified strategic improvement opportunities, all of which reflect the Company's expectations based upon currently available information and data. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

    Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, our ability to continue as a going concern; our potential need to raise additional capital to fund our existing operations or develop and commercialize new services or expand our operations; our ability to achieve or maintain profitability; our ability to maintain compliance with our debt covenants in the future, or obtain required waivers from our lenders if future operating performance were to fall below current projections, and if there are material changes to management's assumptions, we could be required to recognize non-cash charges to operating earnings for goodwill and/or other intangible asset impairment; our ability to identify and develop successful new geographies, physician partners, payors and patients; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; our ability to fund our growth and expand our operations; changes in laws and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payors; the impact of fluctuations in risk adjustments; our ability to establish and maintain effective internal controls and the impact of material weaknesses we have identified; our ability to maintain the listing of our securities on Nasdaq; increased labor costs and medical expense; our ability to recruit and retain qualified team members and independent physicians; and the factors described under Part I, Item 1A. "Risk Factors" and Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2024, and in our subsequent filings with the SEC.

    All information in this press release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law. You are cautioned not to place undue reliance on any forward-looking statements contained in this press release.

    P3 HEALTH PARTNERS INC. and SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except per share amounts)

    (unaudited)

     

     

    March 31, 2025

     

    December 31, 2024

    ASSETS

     

     

     

    CURRENT ASSETS:

     

     

     

    Cash

    $

    40,082

     

     

    $

    38,816

     

    Restricted cash

     

    1,211

     

     

     

    5,286

     

    Health plan receivable, net of allowance for credit losses of $150

     

    129,350

     

     

     

    121,266

     

    Clinic fees, insurance and other receivable

     

    5,409

     

     

     

    3,947

     

    Prepaid expenses and other current assets

     

    14,980

     

     

     

    14,422

     

    Assets held for sale

     

    403

     

     

     

    403

     

    TOTAL CURRENT ASSETS

     

    191,435

     

     

     

    184,140

    Property and equipment, net

     

    5,308

     

     

     

    5,734

     

    Intangible assets, net

     

    553,889

     

     

     

    574,350

     

    Other long-term assets

     

    33,238

     

     

     

    19,196

     

    TOTAL ASSETS (1)

    $

    783,870

     

     

    $

    783,420

     

    LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY

     

     

     

    CURRENT LIABILITIES:

     

     

     

    Accounts payable

    $

    11,503

     

     

    $

    8,442

     

    Accrued expenses and other current liabilities

     

    27,971

     

     

     

    29,416

     

    Accrued payroll

     

    3,216

     

     

     

    2,722

     

    Health plan settlements payable

     

    56,715

     

     

     

    55,565

     

    Claims payable

     

    268,664

     

     

     

    255,089

     

    Premium deficiency reserve

     

    60,406

     

     

     

    67,368

     

    Accrued interest

     

    12,410

     

     

     

    12,460

     

    Current portion of long-term debt

     

    65,000

     

     

     

    65,000

     

    Short-term debt

     

    796

     

     

     

    —

     

    Liabilities held for sale

     

    353

     

     

     

    353

     

    TOTAL CURRENT LIABILITIES

     

    507,034

     

     

     

    496,415

     

    Operating lease liability

     

    10,981

     

     

     

    11,339

     

    Warrant liabilities

     

    6,990

     

     

     

    10,312

     

    Long-term debt, net

     

    106,121

     

     

     

    89,824

     

    Other Long-Term Liabilities

     

    31,665

     

     

     

    26,001

     

    TOTAL LIABILITIES (1)

     

    662,791

     

     

     

    633,891

     

    COMMITMENTS AND CONTINGENCIES

     

     

     

    MEZZANINE EQUITY:

     

     

     

    Redeemable non-controlling interest

     

    57,829

     

     

     

    73,593

     

    STOCKHOLDERS' EQUITY:

     

     

     

    Class A common stock, $0.0001 par value; 800,000 shares authorized; 3,263 and 3,257 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively

     

    —

     

     

     

    —

     

    Class V common stock, $0.0001 par value; 205,000 shares authorized; 3,919 shares issued and outstanding as of March 31, 2025 and December 31, 2024

     

    —

     

     

     

    —

     

    Additional paid in capital

     

    586,923

     

     

     

    579,129

     

    Accumulated deficit

     

    (523,673

    )

     

     

    (503,193

    )

    TOTAL STOCKHOLDERS' EQUITY

     

    63,250

     

     

     

    75,936

     

    TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY

    $

    783,870

     

     

    $

    783,420

     

    (1)

     

    The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). As discussed in Note 13 "Variable Interest Entities," P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC's consolidated VIEs totaling $10.7 million and $9.3 million as of March 31, 2025 and December 31, 2024, respectively, and total liabilities of P3 LLC's consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $15.6 million and $14.9 million as of March 31, 2025 and December 31, 2024, respectively. These VIE assets and liabilities do not include $41.1 million and $40.3 million of net amounts due to affiliates as of March 31, 2025 and December 31, 2024, respectively, as these are eliminated in consolidation and not presented within the consolidated balance sheets.

    All periods presented have been retroactively adjusted to reflect the 1-for-50 reverse stock split effected on April 11, 2025.

    P3 HEALTH PARTNERS INC. and SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share amounts)

    (unaudited)

     

     

    Three Months Ended March 31,

     

    2025

     

    2024

    OPERATING REVENUE:

     

     

     

    Capitated revenue

    $

    369,517

     

     

    $

    384,134

     

    Other patient service revenue

     

    3,708

     

     

     

    4,354

     

    TOTAL OPERATING REVENUE

     

    373,225

     

     

     

    388,488

     

    OPERATING EXPENSE:

     

     

     

    Medical expense

     

    372,043

     

     

     

    382,057

     

    Premium deficiency reserve

     

    (6,962

    )

     

     

    1,000

     

    Corporate, general and administrative expense

     

    24,999

     

     

     

    27,401

     

    Sales and marketing expense

     

    181

     

     

     

    322

     

    Depreciation and amortization

     

    21,052

     

     

     

    21,539

     

    TOTAL OPERATING EXPENSE

     

    411,313

     

     

     

    432,319

     

    OPERATING LOSS

     

    (38,088

    )

     

     

    (43,831

    )

    OTHER INCOME (EXPENSE):

     

     

     

    Interest expense, net

     

    (8,725

    )

     

     

    (4,256

    )

    Mark-to-market of stock warrants

     

    3,322

     

     

     

    216

     

    Other

     

    318

     

     

     

    337

     

    TOTAL OTHER (EXPENSE) INCOME

     

    (5,085

    )

     

     

    (3,703

    )

    LOSS BEFORE INCOME TAXES

     

    (43,173

    )

     

     

    (47,534

    )

    PROVISION FOR INCOME TAXES

     

    (1,073

    )

     

     

    (2,072

    )

    NET LOSS

     

    (44,246

    )

     

     

    (49,606

    )

    LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST

     

    (23,766

    )

     

     

    (30,906

    )

    NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST

    $

    (20,480

    )

     

    $

    (18,700

    )

     

     

     

     

    NET LOSS PER SHARE:

     

     

     

    Basic

    $

    (6.28

    )

     

    $

    (7.86

    )

    Diluted

    $

    (6.28

    )

     

    $

    (7.86

    )

     

     

     

     

    WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:

     

     

     

    Basic

     

    3,260

     

     

     

    2,378

     

    Diluted

     

    3,260

     

     

     

    2,378

     

    All periods presented have been retroactively adjusted to reflect the 1-for-50 reverse stock split effected on April 11, 2025.

    P3 HEALTH PARTNERS INC. and SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (unaudited)

     

     

    Three Months Ended March 31,

     

    2025

     

    2024

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

    Net loss

    $

    (44,246

    )

     

    $

    (49,606

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Depreciation and amortization

     

    21,052

     

     

     

    21,539

     

    Equity-based compensation

     

    1,808

     

     

     

    1,449

     

    Amortization of original issue discount and debt issuance costs

     

    331

     

     

     

    (140

    )

    Mark-to-market adjustment of stock warrants

     

    (3,322

    )

     

     

    (216

    )

    Premium deficiency reserve

     

    (6,962

    )

     

     

    1,000

     

    Changes in operating assets and liabilities:

     

     

     

    Health plan receivable

     

    (8,084

    )

     

     

    (25,198

    )

    Clinic fees, insurance, and other receivable

     

    (1,462

    )

     

     

    2,892

     

    Prepaid expenses and other current assets

     

    (558

    )

     

     

    (3,296

    )

    Other long-term assets

     

    (14,345

    )

     

     

    (17

    )

    Accounts payable, accrued expenses, and other current liabilities

     

    1,593

     

     

     

    (5,553

    )

    Accrued payroll

     

    494

     

     

     

    1,542

     

    Health plan settlements payable

     

    1,150

     

     

     

    (12,944

    )

    Claims payable

     

    13,575

     

     

     

    44,168

     

    Accrued interest

     

    5,614

     

     

     

    4,387

     

    Operating lease liability

     

    (104

    )

     

     

    (37

    )

    Net cash used in operating activities

     

    (33,466

    )

     

     

    (20,030

    )

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

    Net cash provided by (used in) investing activities

     

    —

     

     

     

    —

     

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

    Proceeds from long-term debt, net of original issue discount

     

    30,000

     

     

     

    10,000

     

    Payment of debt issuance costs

     

    (139

    )

     

     

    —

     

    Proceeds from at-the-market sales, net of offering costs paid

     

    —

     

     

     

    33

     

    Payment of tax withholdings upon settlement of restricted stock unit awards

     

    —

     

     

     

    (73

    )

    Repayment of short-term and long-term debt

     

    (341

    )

     

     

    (430

    )

    Proceeds from short-term debt

     

    1,137

     

     

     

    1,871

     

    Net cash provided by financing activities

     

    30,657

     

     

     

    11,401

     

    Net change in cash and restricted cash

     

    (2,809

    )

     

     

    (8,629

    )

    Cash and restricted cash, beginning of period

     

    44,102

     

     

     

    40,934

     

    Cash and restricted cash, end of period

    $

    41,293

     

     

    $

    32,305

     

    RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA LOSS

    (in thousands, except PMPM)

    (unaudited)

     

     

    Three Months Ended March 31,

    2025

     

    2024

    Net loss

    $

    (44,246

    )

     

    $

    (49,606

    )

    Interest expense, net

     

    8,725

     

     

     

    4,256

     

    Depreciation and amortization

     

    21,052

     

     

     

    21,539

     

    Income tax provision

     

    1,073

     

     

     

    2,072

     

    Mark-to-market of stock warrants

     

    (3,322

    )

     

     

    (216

    )

    Premium deficiency reserve

     

    (6,962

    )

     

     

    1,000

     

    Equity-based compensation

     

    1,808

     

     

     

    1,449

     

    Other(1)

     

    (318

    )

     

     

    (264

    )

    Adjusted EBITDA loss

    $

    (22,190

    )

     

    $

    (19,770

    )

    Adjusted EBITDA loss PMPM

    $

    (64

    )

     

    $

    (52

    )

    ____________________

    (1)

     

    Other during the three months ended March 31, 2025 consisted of (i) interest income, (ii) legal settlements, and (iii) valuation allowance on our notes receivable. Other during the three months ended March 31, 2024 consisted of (i) interest income partially offset by (ii) valuation allowance on our notes receivable.

    MEDICAL MARGIN

    (in thousands, except PMPM)

    (unaudited)

     

     

    Three Months Ended March 31,

     

    2025

     

    2024

    Capitated revenue

    $

    369,517

     

     

    $

    384,134

     

    Less: medical claims expense

     

    (352,317

    )

     

     

    (347,582

    )

    Medical margin

    $

    17,200

     

     

    $

    36,552

     

    Medical margin PMPM

    $

    49

     

     

    $

    96

     

    RECONCILIATION OF GROSS PROFIT (LOSS) TO MEDICAL MARGIN

    (in thousands)

     

     

    Three Months Ended March 31,

    2025

     

    2024

    Gross profit (loss)

    $

    1,182

     

     

    $

    6,431

     

    Other patient service revenue

     

    (3,708

    )

     

     

    (4,354

    )

    Other medical expense

     

    19,726

     

     

     

    34,475

     

    Medical margin

    $

    17,200

     

     

    $

    36,552

     

    RECONCILIATION OF TOTAL OPERATING EXPENSE TO ADJUSTED OPERATING EXPENSE

    (in thousands)

    (unaudited)

     

     

    Three Months Ended March 31,

    2025

     

    2024

    Total operating expense

    $

    411,313

     

     

    $

    432,319

     

    Medical expense

     

    (372,043

    )

     

     

    (382,057

    )

    Depreciation and amortization

     

    (21,052

    )

     

     

    (21,539

    )

    Premium deficiency reserve

     

    6,962

     

     

     

    (1,000

    )

    Equity-based compensation

     

    (1,808

    )

     

     

    (1,449

    )

    Other

     

    62

     

     

     

    (52

    )

    Adjusted operating expense

    $

    23,434

     

     

    $

    26,222

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250515834938/en/

    Ryan Halsted

    Investor Relations

    Gilmartin Group

    [email protected]

    Get the next $PIII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PIII

    DatePrice TargetRatingAnalyst
    4/1/2024Buy → Neutral
    BTIG Research
    9/1/2023$5.00Buy
    BTIG Research
    6/30/2023Market Perform
    TD Cowen
    1/4/2022Outperform
    William Blair
    More analyst ratings

    $PIII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • P3 Health Partners Announces First Quarter 2025 Results

       Affirming 2025 guidance Management to Host Conference Call and Webcast May 15, 2025 at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2025, and affirmed its 2025 guidance. "Our physician-led care enablement model continues to differentiate P3, delivering meaningful improvements in quality measures and cost management through deeper provider partnerships," said Aric Coffman, CEO of P3. "Our turnaround plan is ahead of schedule, with three of four markets already achieving breakeven or better in Q1. Beyond our ori

      5/15/25 4:18:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Schedules First Quarter 2025 Earnings Release and Conference Call

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for first quarter 2025 and file its Quarterly Report on Form 10-Q on Thursday, May 15, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health First Quarter Earnings Conference Call Date & Time May 15, 2025, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partners call

      5/8/25 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners to Participate in the 24th Annual Needham Virtual Healthcare Conference

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. Management will give a presentation on Thursday, April 10, 2025, at 9:45 AM Pacific Time. A webcast of the presentation will be available on P3's Investor Relations Website at https://ir.p3hp.org/. A replay will be available on P3's investor relations webpage for 30 days following the presentation. About P3 Health Partners (NASDAQ:PIII): P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the

      4/2/25 8:05:00 AM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    SEC Filings

    See more
    • P3 Health Partners Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - P3 Health Partners Inc. (0001832511) (Filer)

      6/3/25 5:21:56 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by P3 Health Partners Inc.

      10-Q - P3 Health Partners Inc. (0001832511) (Filer)

      5/15/25 4:57:48 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - P3 Health Partners Inc. (0001832511) (Filer)

      5/15/25 4:16:39 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PIII
    Financials

    Live finance-specific insights

    See more

    $PIII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Chicago Pacific Founders Ugp Iii, Llc bought $81,552 worth of shares (160,000 units at $0.51) (SEC Form 4)

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      9/13/24 9:56:09 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Large owner Chicago Pacific Founders Ugp Iii, Llc bought $128,624 worth of shares (240,000 units at $0.54) (SEC Form 4)

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      9/12/24 8:12:24 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Large owner Chicago Pacific Founders Ugp Iii, Llc bought $117,544 worth of shares (240,000 units at $0.49) (SEC Form 4)

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      9/11/24 6:17:20 AM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Announces First Quarter 2025 Results

       Affirming 2025 guidance Management to Host Conference Call and Webcast May 15, 2025 at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2025, and affirmed its 2025 guidance. "Our physician-led care enablement model continues to differentiate P3, delivering meaningful improvements in quality measures and cost management through deeper provider partnerships," said Aric Coffman, CEO of P3. "Our turnaround plan is ahead of schedule, with three of four markets already achieving breakeven or better in Q1. Beyond our ori

      5/15/25 4:18:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Schedules First Quarter 2025 Earnings Release and Conference Call

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for first quarter 2025 and file its Quarterly Report on Form 10-Q on Thursday, May 15, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health First Quarter Earnings Conference Call Date & Time May 15, 2025, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partners call

      5/8/25 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results

      Revenue increased 18% year-over-year to $1.50 billion Affirming 2025 guidance Management to Host Conference Call and Webcast [March 27, 2025] at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient- centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and affirmed its 2025 guidance. "Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention," said Aric Coffman, CEO of P3. "With the $130M+ in identified programmatic opportunities advancing our path to financial su

      3/27/25 4:22:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • SEC Form 4 filed by Large owner Chicago Pacific Founders Ugp Iii, Llc

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      6/6/25 4:07:13 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • SEC Form 4 filed by Large owner Chicago Pacific Founders Ugp Iii, Llc

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      1/31/25 7:05:33 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • SEC Form 3 filed by new insider Pedersen Leif Elliott

      3 - P3 Health Partners Inc. (0001832511) (Issuer)

      10/1/24 5:35:14 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Leadership Updates

    Live Leadership Updates

    See more
    • P3 Health Partners Names Leif Pedersen New Chief Financial Officer

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, announced today that Leif Pedersen, an experienced finance, operational and value-based care executive, will join the company as chief financial officer (CFO) effective October 1, 2024. Pedersen succeeds Atul Kavthekar, who will continue as CFO until September 30, 2024, after which he will serve as a Strategic Advisor to the company. Pedersen was most recently Vice President of Finance & CFO Shared Services for Optum Health, a division of UnitedHealth Group. Prior to Optum Health, Pedersen served as Vice President of Finance & CFO IT at DaVita Medical Group. He brings m

      8/29/24 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Names Dr. Aric Coffman as CEO

      P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), today named Dr. Aric Coffman as P3's Chief Executive Officer, effective as of May 8, 2024, succeeding Dr. Sherif Abdou, P3's Co-Founder. Dr. Abdou will continue to serve as a Strategic Advisor to P3, and a member of the Company's Board of Directors working closely with Dr. Coffman to ensure a smooth transition. Dr. Coffman is an exceptional physician leader with a proven track record of success in the value-based care sector, most recently as the CEO of Honest Medical Group, a Rubicon Founders portfolio company. He brings over two decades of experience in leading provider organizations in delivering high quality, highly effici

      5/8/24 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PIII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G filed by P3 Health Partners Inc.

      SC 13G - P3 Health Partners Inc. (0001832511) (Subject)

      11/14/24 4:33:46 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by P3 Health Partners Inc.

      SC 13D/A - P3 Health Partners Inc. (0001832511) (Subject)

      11/8/24 5:15:05 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by P3 Health Partners Inc.

      SC 13D/A - P3 Health Partners Inc. (0001832511) (Subject)

      6/26/24 4:30:49 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners downgraded by BTIG Research

      BTIG Research downgraded P3 Health Partners from Buy to Neutral

      4/1/24 7:39:12 AM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • BTIG Research initiated coverage on P3 Health Partners with a new price target

      BTIG Research initiated coverage of P3 Health Partners with a rating of Buy and set a new price target of $5.00

      9/1/23 7:31:24 AM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • TD Cowen initiated coverage on P3 Health Partners

      TD Cowen initiated coverage of P3 Health Partners with a rating of Market Perform

      6/30/23 7:34:42 AM ET
      $PIII
      Medical/Nursing Services
      Health Care